We are live on ! Find out more
ALDX icon

Aldeyra Therapeutics

125 hedge funds and large institutions have $226M invested in Aldeyra Therapeutics in 2025 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 27 increasing their positions, 47 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

66% more call options, than puts

Call options by funds: $5.79M | Put options by funds: $3.49M

64% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 14

22% more capital invested

Capital invested by funds: $186M → $226M (+$40M)

6% more funds holding

Funds holding: 118125 (+7)

1% more ownership

Funds ownership: 62.45%63.45% (+1%)

43% less repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 47

Holders
125
Holders Change
+7
Holders Change %
+5.93%
% of All Funds
1.68%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
23
Increased
27
Reduced
47
Closed
14
Calls
$5.79M
Puts
$3.49M
Net Calls
+$2.3M
Net Calls Change
+$857K

ALDX Hedge Fund Activity: Q1 2025 in Review

125 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q1 2025, worth a combined $226M — up 22% from $186M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new ALDX positions and 14 closed out — a net gain of 9 holders — while 27 added to existing stakes and 47 trimmed.

The largest buyer was Kingdon Capital Management, opening a new position worth an estimated $4.6M. The largest seller was ADAR1 Capital Management, cutting an estimated $2.58M.

  • 125 institutional investors held Aldeyra Therapeutics (ALDX) as of Q1 2025, up from 118 in Q4 2024.
  • Funds reported $226M of Aldeyra Therapeutics stock for Q1 2025, up 22% quarter-over-quarter.
  • 23 funds opened new Aldeyra Therapeutics positions in Q1 2025 and 14 closed out, a net change of +9 holders.
  • The largest Aldeyra Therapeutics buyer in Q1 2025 was Kingdon Capital Management, an estimated $4.6M added.
  • The largest Aldeyra Therapeutics seller in Q1 2025 was ADAR1 Capital Management, an estimated $2.58M sold.

Based on aggregated 13F filings for Q1 2025.